These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 12521997)

  • 21. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
    Dawicki W; Bertram EM; Sharpe AH; Watts TH
    J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo.
    Yamada A; Salama AD; Sho M; Najafian N; Ito T; Forman JP; Kewalramani R; Sandner S; Harada H; Clarkson MR; Mandelbrot DA; Sharpe AH; Oshima H; Yagita H; Chalasani G; Lakkis FG; Auchincloss H; Sayegh MH
    J Immunol; 2005 Feb; 174(3):1357-64. PubMed ID: 15661893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
    J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.
    Brown GR; Lee E; Thiele DL
    J Immunol; 2002 Mar; 168(6):3065-71. PubMed ID: 11884480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen.
    Kinnear G; Wood KJ; Fallah-Arani F; Jones ND
    J Immunol; 2013 Aug; 191(3):1465-75. PubMed ID: 23817421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of rat OX40 ligand by monoclonal antibody.
    Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
    Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity.
    Soroosh P; Ine S; Sugamura K; Ishii N
    J Immunol; 2006 May; 176(10):5975-87. PubMed ID: 16670306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of OX40 gene expression in graft-versus-host disease.
    Miura Y; Thoburn CJ; Bright EC; Arai S; Hess AD
    Transplant Proc; 2005; 37(1):57-61. PubMed ID: 15808546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses.
    Ishii N; Ndhlovu LC; Murata K; Sato T; Kamanaka M; Sugamura K
    Eur J Immunol; 2003 Sep; 33(9):2372-81. PubMed ID: 12938213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
    J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease.
    Lamb LS; Abhyankar SA; Hazlett L; O'Neal W; Folk RS; Vogt S; Parrish RS; Bridges K; Henslee-Downey PJ; Gee AP
    Cytometry; 1999 Oct; 38(5):238-43. PubMed ID: 10516610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central Roles of OX40L-OX40 Interaction in the Induction and Progression of Human T Cell-Driven Acute Graft-versus-Host Disease.
    Tripathi T; Yin W; Xue Y; Zurawski S; Fujita H; Hanabuchi S; Liu YJ; Oh S; Joo H
    Immunohorizons; 2019 Mar; 3(3):110-120. PubMed ID: 31240276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
    Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
    Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
    Yoshioka T; Nakajima A; Akiba H; Ishiwata T; Asano G; Yoshino S; Yagita H; Okumura K
    Eur J Immunol; 2000 Oct; 30(10):2815-23. PubMed ID: 11069062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of the OX40 ligand prolongs corneal allograft survival.
    Hattori T; Usui Y; Okunuki Y; Sonoda Y; Usui M; Takada E; Mizuguchi J; Yagita H; Okumura K; Akiba H; Takeuchi M
    Eur J Immunol; 2007 Dec; 37(12):3597-604. PubMed ID: 18022861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.